NEW YORK, November 9, 2022 /PRNewswire/ — The “Anaplastic Thyroid Cancer Drugs Market by Product and Geography: Forecast and Analysis 2022-2026The report has been added to the Technavio offer. The report expects the market size to grow by $230.53 million, accelerating at a CAGR of 5.44% during the forecast period. The global market for anaplastic thyroid cancer drugs is fragmented with more than 20 companies and various types of brand and generic drugs of some chemotherapeutics. Competition is high among providers due to the introduction of new therapies in the market. Additionally, the presence of a strong pipeline of drugs used to treat anaplastic thyroid cancer will further intensify competition during the forecast period. In addition, the market will witness approvals for some drugs during the forecast period, which will intensify competition among vendors. Get deeper insights into the vendor landscape and make informed decisions. Buy report now!
Anaplastic Thyroid Cancer Drugs Market 2022-2026: Segmentation
With a focus on identifying the dominant industry influencers, Technavio reports present a detailed study by way of synthesizing and summarizing data from multiple sources. This report offers up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment.
The report also covers the following areas:
Anaplastic Thyroid Cancer Drugs Market 2022-2026: Segmentation
Market growth will be significant in the chemotherapy segment during the forecast period. The growth of the chemotherapy segment can be attributed primarily to the high prevalence of thyroid cancer as chemotherapy is the second-line treatment for anaplastic thyroid cancer after surgery. The incidence rate of thyroid cancer is increasing at a significant rate, almost tripling every ten years. Although most thyroid tumors are curable, about 2% to 3% of thyroid cancers are refractory to standard treatments. These types include undifferentiated, highly aggressive, and mostly chemoresistant tumors and are known as anaplastic thyroid cancer.
37% of market growth will come from North America during the forecast period. The growth of the market in North America is mainly attributed to the increase in thyroid cancer cases in the region. The increase in the geriatric population in the region is another factor driving the growth of the anaplastic thyroid cancer drug market in North America.
Identify other potential segments and regions in the market. Download free sample report
Anaplastic Thyroid Cancer Drugs Market 2022-2026: Analysis and Vendor Scope
Some of the major suppliers to the anaplastic thyroid cancer drug market in the industry 14 include Akorn Inc., Amneal Pharmaceuticals Inc., Bayer AG, Bristol Myers Squibb Co., Cipla Ltd., Daiichi Sankyo Co. Ltd., Dr. Reddys Laboratories Ltd., Eisai Co. Ltd., Exelixis Inc., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson, Medtronic Plc, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd. , Takeda Pharmaceutical Co. Ltd. and Viatris Inc.
To help companies improve their position in the market, the Technavio report provides a detailed analysis of around 25 vendors operating in the market. Backed with competitive intelligence and benchmarking, our Anaplastic Thyroid Cancer Drugs market research report is designed to provide entry, customer profile, and M&A support, as well as go-to-market strategy support.
The high prevalence of thyroid cancer, the introduction of targeted therapies, and the growing geriatric population will offer immense opportunities for growth. To take advantage of current opportunities, market vendors must strengthen their position in fast-growing segments while maintaining their positions in slow-growing segments.
Technavio’s library includes more than 17,000 reports covering more than 2,000 emerging technologies. Subscribe to our “Basic Plan” in just US$5,000 and get lifetime access to Technavio Insights
Anaplastic Thyroid Cancer Drugs Market 2022-2026: Key Highlights
-
Market CAGR during the forecast period 2022-2026
-
Detailed information on factors that will assist anaplastic thyroid cancer drug market growth during the next five years.
-
Anaplastic Thyroid Cancer Drugs Market Size Estimation and Its Contribution to the Parent Market
-
Predictions about upcoming trends and changes in consumer behavior
-
The growth of the anaplastic thyroid cancer drug market
-
Analysis of the competitive landscape of the market and detailed information on the suppliers.
-
Comprehensive details of factors that will challenge the growth of anaplastic thyroid cancer drug market vendors
Related Reports:
-
the BRAF Kinase Inhibitors Market The stock is expected to accelerate at a CAGR of 7.73% and reach an estimated value of $1.19 billion by 2026. The high affinity and specificity of BRAF kinase inhibitors is notably driving the growth of the BRAF kinase inhibitors market, although factors such as the availability of substitute therapies may impede market growth.
-
the cancer biologics market participation is expected to increase in $34.97 billion from 2021 to 2026, and the market growth momentum will accelerate at a CAGR of 8.91%. The rising global incidence of cancer is notably driving the growth of the cancer biologics market, although factors such as the high cost of cancer biologics may impede market growth.
|
Scope of the anaplastic thyroid cancer drug market |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
base year |
2021 |
|
forecast period |
2022-2026 |
|
Growth momentum and CAGR |
Accelerates to a CAGR of 5.44% |
|
Market growth 2022-2026 |
$230.53 million |
|
market structure |
Fragmented |
|
YoY growth (%) |
4.29 |
|
regional analysis |
North America, Europe, Asia and Rest of the World (ROW) |
|
Contribution to the real market |
North America at 37% |
|
Main consuming countries |
United States, Canada, Italy, China and India |
|
competitive landscape |
Leading companies, competitive strategies, scope of consumer engagement |
|
Profiled companies |
Akorn Inc., Amneal Pharmaceuticals Inc., Bayer AG, Bristol Myers Squibb Co., Cipla Ltd., Daiichi Sankyo Co. Ltd., Dr. Reddys Laboratories Ltd., Eisai Co. Ltd., Exelixis Inc., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson, Medtronic Plc, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Viatris Inc. |
|
market dynamics |
Major market analysis, market growth drivers and obstacles, fast and slow growing segments analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period. |
|
Customization Scope |
If our report didn’t include the data you’re looking for, you can contact our analysts and get custom segments. |
Table of Contents:
1. Executive Summary
2 Market Landscape
3 Market size
4 Five Forces Analysis
5 Market segmentation by product
6 Customer landscape
7 Geographic Landscape
8 drivers, challenges and trends
9 Provider Landscape
10 Supplier Analysis
11 Appendix
About us
Technavio is a world leader in technology research and consulting. His research and analysis focus on emerging market trends and provide actionable insights to help companies identify market opportunities and develop effective strategies to optimize their market positions. With more than 500 specialist analysts, Technavio’s reporting library consists of more than 17,000 reports and counting, covering 800 technologies and spanning 50 countries. Its client base consists of companies of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, in-depth research, and actionable market insights to identify opportunities in existing markets and and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Mayda
Media and Marketing Executive
USA: +1 844 364 1100
United Kingdom: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download media:https://www.prnewswire.com/news-releases/anaplastic-thyroid-cancer-drugs-market-to-record-usd-230-53-mn-growth-akorn-inc-amneal-pharmaceuticals-inc-bayer- ag-identified-as-key-suppliers—technavio-301671305.html
SOURCE Technavio